NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.80 +1.43%

+$0.06 today

Market cap
$124.12M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 2.09M

Average 1.27M

NRXP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

NRx Pharmaceuticals, Inc.NASDAQ: NRXP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 25.5%

Gross margin was 25.5% in Q1 FY2026. On a trailing-twelve-month basis it was 37.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
25.5%-22.9 pp QoQ
Last fiscal yearDec 2025
58.8%— YoY
LTMMar 2026
37.1%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
58.8%
Year-over-year change
—

Gross Margin vs competitors

How NRXP compares with its peers on the latest reported figures

  • NRXP's LTM Mar 2026 gross margin of 37.1% is the 6th highest of the 7 companies compared; the peer median is 87.6%.
NRXP Competitors Peer median
Gross Margin for NRXP and competitors
Company Period LTM level YoY 3-year change
CUECue Biopharma, Inc.LTM Mar 202699.8% -0.2 pp+0.0 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 202696.0% -0.1 pp-0.8 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 202687.2% +59.0 pp—
HOWLWerewolf Therapeutics, Inc.LTM Jun 202686.4% ——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
EQEquillium, Inc.FY2025— ——
Peer median (excluding NRXP) 87.6%-0.2 pp-0.8 pp

Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00001.23M
Cost of Revenue2K4K5K5K505K
Gross Profit(2K)(4K)(5K)(5K)720K
Gross Margin————58.8%
Research & Development20.26M17.03M13.37M6.2M3.78M
Selling, General & Admin74.94M27.3M14.21M13.5M13.06M
Operating Expenses95.2M44.33M27.58M19.7M16.94M
Depreciation & Amortization2K4K5K5K143K
EBITDA(93.04M)(39.75M)(30.03M)(24.04M)(27.81M)
EBITDA Margin————-2270.0%
Operating Income(95.2M)(44.34M)(27.59M)(19.7M)(16.22M)
Operating Margin————-1324.4%
Interest Income18249K494K44K12K
Interest Expense18K0120K1.08M671K
Other Income / Expenses2.14M4.58M(2.56M)(5.42M)(12.4M)
Income Before Tax(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Pre-Tax Margin————-2336.5%
Income Tax Expense00000
Net Income(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Net Margin————-2336.5%
EPS (Basic)(7.44)(0.60)(3.98)(2.39)(1.34)
EPS (Diluted)(7.44)(0.60)(3.98)(2.39)(1.34)
Weighted Avg Shares46.92M65.77M7.58M10.52M21.4M
Weighted Avg Shares (Diluted)46.92M65.77M7.58M10.52M21.4M

NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.